ClariTrial | Search Clinical Trials

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

152 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Phase 3Multiple Sclerosis (MS) Primary Progressive

OrelabrutinibPlacebo

Zenas BioPharma (USA), LLC705 participants68 sites · United States, Bulgaria, CroatiaCompletes Jun 2030

Compare CT.gov Full analysis →

Recruiting

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Phase 3Multiple Sclerosis

Ocrelizumab

Hoffmann-La Roche500 participants44 sites · France, Germany, RussiaCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Phase 2Neuromyelitis Optica Spectrum Disorder

Inebilizumab

Amgen15 participants19 sites · United States, Argentina, BrazilCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Phase 3Acute Ischemic StrokeCerebral Stroke

Drug: Normal SalineSovateltide

Pharmazz, Inc.514 participants54 sites · United States, Germany, SpainCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Phase 2AgitationAlzheimer Disease

BMS-986368Placebo

Celgene120 participants77 sites · United States, Argentina, AustraliaCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Azathioprine in MOGAD

Phase 3Central Nervous System InflammationMOG-IgG Associated Disease

AzathioprinePlacebo

Hospices Civils de Lyon126 participants17 sites · FranceCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Phase 2Parkinson Disease

PlaceboVarenicline

Vikas Kotagal102 participants1 site · United StatesCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Phase 3Focal SeizureEpilepsyFocal Epilepsy

RAP-219RAP-219Placebo

Rapport Therapeutics Inc.333 participants16 sites · United States, South KoreaCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations

Phase 3PARKINSON DISEASE (Disorder)PainPain Management

SafinamidePlacebo

Universita di Verona60 participants1 site · ItalyCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Phase 2Phase 3Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis

Cladribine Subcutaneous Injection0.9% Chloride Injection Sodium

Institute of Psychiatry and Neurology, Warsaw188 participants1 site · PolandCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage

Phase 3Intracerebral Haemorrhage

Aspirin 75 mg dailyPlacebo

Christian Medical College and Hospital, Ludhiana, India5,676 participants33 sites · IndiaCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Phase 3Dravet Syndrome

zorevunersenSham Comparator

Stoke Therapeutics, Inc170 participants61 sites · United States, China, FranceCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Phase 2Epilepsies, Partial

Cenobamate

Ono Pharmaceutical Co., Ltd.100 participants29 sites · JapanCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

Phase 3PARKINSON DISEASE (Disorder)

LECIG (levodopa, carbidopa, entacapone intestinal gel)Best oral medication

University Hospital Tuebingen150 participants7 sites · GermanyCompletes Sep 2030

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

Phase 3Ischemic Stroke

SP-8203Placebo

Shin Poong Pharmaceutical Co. Ltd.852 participants2 sites · South KoreaCompletes Mar 2027

Compare CT.gov Full analysis →

1–15 of 152

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

152 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Phase 3Multiple Sclerosis (MS) Primary Progressive

OrelabrutinibPlacebo

Zenas BioPharma (USA), LLC705 participants68 sites · United States, Bulgaria, CroatiaCompletes Jun 2030

Compare CT.gov Full analysis →

Recruiting

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

Phase 3Multiple Sclerosis

Ocrelizumab

Hoffmann-La Roche500 participants44 sites · France, Germany, RussiaCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Phase 2Neuromyelitis Optica Spectrum Disorder

Inebilizumab

Amgen15 participants19 sites · United States, Argentina, BrazilCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Phase 3Acute Ischemic StrokeCerebral Stroke

Drug: Normal SalineSovateltide

Pharmazz, Inc.514 participants54 sites · United States, Germany, SpainCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Phase 2AgitationAlzheimer Disease

BMS-986368Placebo

Celgene120 participants77 sites · United States, Argentina, AustraliaCompletes Nov 2027

Compare CT.gov Full analysis →

Recruiting

Azathioprine in MOGAD

Phase 3Central Nervous System InflammationMOG-IgG Associated Disease

AzathioprinePlacebo

Hospices Civils de Lyon126 participants17 sites · FranceCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

Phase 2Parkinson Disease

PlaceboVarenicline

Vikas Kotagal102 participants1 site · United StatesCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Phase 3Focal SeizureEpilepsyFocal Epilepsy

RAP-219RAP-219Placebo

Rapport Therapeutics Inc.333 participants16 sites · United States, South KoreaCompletes Jul 2029

Compare CT.gov Full analysis →

Recruiting

Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations

Phase 3PARKINSON DISEASE (Disorder)PainPain Management

SafinamidePlacebo

Universita di Verona60 participants1 site · ItalyCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Phase 2Phase 3Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis

Cladribine Subcutaneous Injection0.9% Chloride Injection Sodium

Institute of Psychiatry and Neurology, Warsaw188 participants1 site · PolandCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage

Phase 3Intracerebral Haemorrhage

Aspirin 75 mg dailyPlacebo

Christian Medical College and Hospital, Ludhiana, India5,676 participants33 sites · IndiaCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Phase 3Dravet Syndrome

zorevunersenSham Comparator

Stoke Therapeutics, Inc170 participants61 sites · United States, China, FranceCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Phase 2Epilepsies, Partial

Cenobamate

Ono Pharmaceutical Co., Ltd.100 participants29 sites · JapanCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

Phase 3PARKINSON DISEASE (Disorder)

LECIG (levodopa, carbidopa, entacapone intestinal gel)Best oral medication

University Hospital Tuebingen150 participants7 sites · GermanyCompletes Sep 2030

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

Phase 3Ischemic Stroke

SP-8203Placebo

Shin Poong Pharmaceutical Co. Ltd.852 participants2 sites · South KoreaCompletes Mar 2027

Compare CT.gov Full analysis →

1–15 of 152